Full-Time

Senior Expert Global Quality Control

Deadline 8/7/26
Roche

Roche

1-10 employees

Global pharmaceuticals and diagnostics company

Compensation Overview

$136.9k - $179.7k/yr

Mississauga, ON, Canada

In Person

Relocation not available.

Category
Biology & Biotech (1)
Required Skills
Microbiology

Get referred to Roche

See people who can refer or advise you

Requirements
  • Advanced degree (Master’s or Ph.D. preferred) in Microbiology, Molecular Biology, Biotechnology
  • At least 10+ years of hands-on microbiological Quality Control experience within the pharmaceutical or biopharmaceutical industry
  • Proven track record of leading international, cross-functional projects, managing QA workflows, and driving change across complex matrix organizations
  • Expert technical mastery in classical microbiology, rapid microbiological methods (RMM), and modern molecular diagnostics
  • In-depth knowledge of global regulatory expectations and pharmacopeial standards, including EU/FDA GMP, GCLP, and ISO requirements
  • Skilled at synthesizing complex scientific concepts into compelling business cases and strategic roadmaps for executive decision-makers
  • Exceptional written and spoken English skills
Responsibilities
  • Establish global Network QC standards, local alignment frameworks, and foundational technical documentation to elevate quality across manufacturing sites
  • Author and review technical dossiers, validation master plans, and scientific justifications to support health authority filings worldwide
  • Formulate forward-looking QC concepts, strategic business cases, and risk-based decision frameworks for executive management
  • Provide specialized scientific consultation and global troubleshooting for complex network investigations, deviations, and out-of-specification (OOS) events
  • Represent Roche Pharma Network QC in prominent international working groups and regulatory forums (such as PDA and ECA) to influence emerging industry standards
  • Drive the global evaluation, development, and validation of alternative and rapid microbiological methods (RMM) across the entire Roche Pharma Quality Control network
  • Direct cross-site harmonization and technology projects to transition legacy assays into modern, automated, or molecular testing platforms

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Get referred to Roche

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • cobas BV/CV clearance expands Roche’s molecular diagnostics menu in women’s health.
  • Susvimo’s European progress strengthens a differentiated continuous-delivery ophthalmology franchise.
  • Roche’s global scale across 100-plus countries supports commercialization and pipeline deployment.

What critics are saying

  • Susvimo still needs European Commission approval before Roche can monetize the label.
  • Diagnostics products face slow lab adoption and pricing pressure after technical clearance.
  • Patent expirations or biosimilar competition can rapidly erode blockbuster pharmaceutical revenue.

What makes Roche unique

  • Founded in Basel in 1896, Roche built quality-focused pharmaceuticals from the start.
  • Genentech acquisition in 2009 made Roche the world’s largest biotechnology company.
  • Roche leads in in-vitro diagnostics alongside medicines, enabling integrated care platforms.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company News

Dealroom.co
Apr 16th, 2026
SAGA company information, funding & investors

SAGA, providing cancer companion diagnostic testing of tissue and non-invasive monitoring of circulating tumor dna (ctdna). Here you'll find information about their funding, investors and team.

Yahoo Finance
Apr 13th, 2026
Roche receives CE mark for Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis

Roche has received CE mark approval for its Elecsys Neurofilament Light Chain blood test to detect neuroinflammation in adults with relapsing remitting multiple sclerosis. The test measures NfL, a protein released during nerve cell injury, providing insight into neuroaxonal damage associated with the disease. Multiple sclerosis affects over 2.9 million people worldwide. Whilst early and regular monitoring is critical, patients often struggle to access routine MRI scans. The minimally invasive blood test offers a more accessible alternative, complementing clinical assessments and potentially enabling earlier intervention. The test runs on Roche's widely available cobas instruments, delivering standardised results and requiring only a simple blood sample. This reduces the need for patients to travel to specialist centres, making frequent monitoring more practical where traditional testing faces geographic, financial or logistical barriers.

Bizwatch
Apr 12th, 2026
Roche invests $20M in degrader-antibody conjugate platform via C4 Therapeutics deal worth up to $1B

Roche has partnered with C4 Therapeutics to develop degrader-antibody conjugates (DACs), marking a $20 million upfront payment with potential milestone payments exceeding $1 billion. The collaboration targets cancer therapeutics using C4's Torpedo platform. DACs represent a next-generation approach to antibody-drug conjugates (ADCs). Whilst ADCs attach cytotoxic drugs to antibodies, DACs use targeted protein degradation payloads to selectively eliminate specific proteins within cancer cells, potentially reducing toxicity and drug resistance whilst accessing previously difficult targets. Amongst Korean listed companies, Orum Therapeutics leads DAC development, having licensed ORM-6151 to Bristol Myers Squibb in 2023. Y-Biologics partnered with Ubix Therapeutics, whilst Oscotec is developing three DAC pipelines through subsidiary Genosco, targeting technology transfers after 2028.

Yahoo Finance
Mar 30th, 2026
Roche gets FDA clearance for cobas c703 and ISE neo lab testing units with 2,000 tests per hour

Roche has received FDA 510(k) clearance for its cobas c703 and cobas ISE neo analytical units, designed to enhance laboratory efficiency through increased automation and testing capacity. The units are part of Roche's cobas pro integrated solutions platform. The cobas c703 delivers up to 2,000 tests per hour with 70 reagent positions, doubling clinical chemistry throughput whilst reducing reagent reloads. The cobas ISE neo provides up to 1,800 tests per hour with automated maintenance, reducing hands-on time and plastic waste compared to previous systems. Both units feature monthly operator maintenance to improve uptime and help laboratories address staffing shortages and growing test volumes. Roche has over 4,000 cobas analysers installed across the United States.

Yahoo Finance
Mar 30th, 2026
Roche launches cobas MPX-E assay, 4-in-1 donor screening test for HIV, HCV, HBV and HEV

Roche has launched the cobas MPX-E assay, a four-in-one donor screening test that simultaneously detects HIV, Hepatitis C, B and E viruses. The test is now available in countries accepting the CE mark. The assay consolidates detection of four major viral targets into a single workflow, improving laboratory efficiency and reducing costs. It features dual-target detection for HIV-1 and enhanced sensitivity for Hepatitis E, which causes an estimated 20 million infections and 70,000 deaths annually worldwide. The test runs on Roche's fully automated cobas x800 systems, which process over 10 million tests monthly across laboratories globally. The ready-to-load reagents enable up to eight hours of walk-away time. The nucleic acid testing blood screening market is valued at approximately 800 million Swiss francs globally, with an expected annual growth rate of 2% through 2029.